Jakarta, October 30, 2026 – PT Enseval Putera Megatrading Tbk ("the Company") recorded net sales of Rp27,104.22 billion in the third quarter of 2026, based on the Company’s unaudited consolidated financial statements and its subsidiaries for the period ended September 30, 2026. This figure represents a 10.93% increase compared to net sales of Rp24,434.73 billion in the third quarter of 2025, reflecting the continuous growth of the Company's business activities.

In line with sales growth, cost of goods sold increased by 10.75% to Rp24,343.93 billion. The Company successfully maintained profitability growth, posting a gross profit of Rp2,760.29 billion—a 12.45% increase compared to the third quarter of 2025.

Operating expenses were recorded at Rp1,855.31 billion, comprising selling expenses of Rp1,668.82 billion and general and administrative expenses of Rp186.48 billion. This represents an 11.35% increase in operating expenses compared to the same period of the previous year. Consequently, the Company posted an operating profit of Rp904.98 billion.

Profit before income tax expense stood at Rp901.15 billion. The composition of other income (expenses) included financial income of Rp8.77 billion, financial expenses of Rp15.61 billion, final tax expenses of Rp2.60 billion, share of net profit of associates of Rp6.45 billion, other operating income of Rp37.64 billion, and other operating expenses of Rp38.49 billion.

Meanwhile, income tax expense was recorded at Rp202.56 billion, increasing by 15.62% compared to Rp175.20 billion in the third quarter of 2025.

As a result, the Company booked a profit for the period of Rp698.59 billion, representing a 15.77% increase compared to the same period of the previous year. This achievement underscores the Company's ability to sustain performance growth amidst operational dynamics and market conditions.

Regarding the consolidated statement of financial position, as of September 30, 2026 (unaudited) compared to December 31, 2025 (audited), the Company’s total assets increased by 8.16% from Rp13.13 trillion to Rp14.20 trillion. Total liabilities increased by 7.39% from Rp5.27 trillion as of December 31, 2025, to Rp5.66 trillion in the third quarter of 2026. Consequently, total equity grew by 8.67% from Rp7.87 trillion to Rp8.55 trillion in the third quarter of 2026.

Performance by Division

Currently, the Company operates 7 divisions: Consumer Products, Prescription Pharmaceuticals, Over-the-Counter (OTC) Pharmaceuticals, Raw Materials for Sale, Medical Devices, Healthcare Services and Transportation, and Veterinary Pharmaceuticals

The performance details of each division are as follows:

• Consumer Products Division: The largest contributor to total net sales, accounting for 36.69%. In the third quarter of 2026, this division recorded net sales of Rp9,945.67 billion, an increase of 8.33% compared to the same period in 2025.
• Prescription Pharmaceuticals Division: The second-largest contributor, accounting for 35.27% of total net sales. Up to the third quarter of 2026, the division recorded net sales of Rp9,560.08 billion, growing by 11.78% compared to the same period in 2025.
• Over-the-Counter (OTC) Pharmaceuticals Division: Recorded net sales of Rp3,896.60 billion in the third quarter of 2026, contributing 14.38% with a 12.35% increase compared to the same period in 2025.
• Raw Materials for Sale Division: Recorded net sales of Rp2,168.65 billion in the third quarter of 2026, an increase of 15.68% compared to the same period in 2025, contributing 8.00%.
• Medical Devices Division: Contributed 5.19% of total net sales in the third quarter of 2026, recording net sales of Rp1,405.50 billion—an increase of 12.50% compared to the same period in 2025.
• Healthcare Services and Transportation Division: Recorded net sales of Rp92.27 billion, an increase of 37.38% compared to the same period in 2025. This division contributed 0.34% to total net sales.

• Veterinary Pharmaceuticals Division: Recorded net sales of Rp35.45 billion, a decrease of 14.58% compared to Rp41.50 billion in the same period of 2025. This division contributed 0.13% to the Company's total net sales.

   

About Enseval

PT Enseval Putera Megatrading Tbk ("Enseval") is one of the largest distribution and logistics companies in Indonesia, having commenced operations in 1973. The Company became a publicly listed entity on August 1, 1994, under the stock ticker symbol EPMT on the Indonesia Stock Exchange.

In addition to distributing Kalbe Group products, Enseval is trusted by various national and international principals. The Company is supported by an extensive distribution network comprising 3 distribution centers in Jakarta, Cikarang, and Surabaya, 48 branches spread across Indonesia, and 24 branches through its subsidiary, PT Tri Sapta Jaya.

To date, the Company has 8 subsidiaries operating in distribution and logistics, raw materials, medical equipment, healthcare, and transportation services.